Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Categories

All Quarterly Result Economy Mutual Fund Business Company Market Budget IPO

Lyka Labs receives product permission for Tofacitinib Ointment

Oct 10, 2023

By: BlinkX Research Team

Lyka Labs has announced a significant development as it receives product permission from the Central Drugs Standard Control Organization of India. The permission is for the manufacture and marketing of Tofacitinib Ointment 2% w/w.

This regulatory milestone comes after Lyka Labs successfully completed a clinical trial involving 125 patients across 8 Clinical Trial Centers within India. The product permission signifies a significant step for the company, expanding its portfolio and potentially offering valuable solutions in the pharmaceutical market.

Stay tuned for further updates from Lyka Labs as it progresses with the launch and marketing of Tofacitinib Ointment 2% w/w.